Advances in post-translational and epigenetic modification of hyperuricemia-to-gout progression: mechanisms and therapeutic targets
Frontiers in Cell and Developmental Biology · 29.05.2026 · 14
DOI: 10.3389/fcell.2026.1749194 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 29.05.2026. Verfasst von Wei Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan …. Die Arbeit nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hyperuricemia (HUA) and gout are endocrine disorders resulting from abnormal uric acid (UA) metabolism, with gout typically developing secondary to HUA and being associated with an exacerbated inflammatory response. Epigenetic modifications and post-translational modifications (PTMs) may contribute to the progression from HUA to gout by modulating the function of UA transporters such as ABCG2 and GLUT9 and involving the NLRP3/IL-β inflammatory axis. However, the specific mechanisms underlying these processes remain incompletely understood. Therefore, this review systematically examines recent research on epigenetic modifications, such as methylation, lactylation, and crotonylation, as well as PTMs including succinylation, phosphorylation, glycosylation, ubiquitination, and acetylation in this process, with the aim of identifying potential therapeutic targets for these two diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
- Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Cardiology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Zitieren
APA
Fu, W., Xu, X., Li, X., Guo, Q., Liu, P., Chen, L., Cheng, W., Zhang, Z., Chen, Z., & Liu, C. (2026). Advances in post-translational and epigenetic modification of hyperuricemia-to-gout progression: mechanisms and therapeutic targets. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1749194
Vancouver
Fu W, Xu X, Li X, Guo Q, Liu P, Chen L, et al. Advances in post-translational and epigenetic modification of hyperuricemia-to-gout progression: mechanisms and therapeutic targets. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1749194
BibTeX
@article{Fu2026,
author = {Fu, Wei and Xu, Xiangman and Li, Xinze and Guo, Qian and Liu, Peng and Chen, Lulu and Cheng, Wenfei and Zhang, Zikuan and Chen, Zilong and Liu, Chuanxin},
title = {Advances in post-translational and epigenetic modification of hyperuricemia-to-gout progression: mechanisms and therapeutic targets},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1749194}
}
EUVIMED